Theriva Biologics (TOVX) Misses Q2 EPS by 1c

Theriva Biologics (NYSE: TOVX) reported Q2 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).

For earnings history and earnings-related data on Theriva Biologics (TOVX) click here.

You May Also Be Interested In

• Electra Therapeutics files for proposed IPO
• Nomura/Instinet Starts Clean Max Enviro Energy Solutions (CLEANMAX:IN) at Buy
• AiRWA receives Nasdaq deficiency notice over late 10-K filing